Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1Breast 1

Conditions

Uveal Melanoma 2Triple Negative Breast Neoplasms 1Osteosarcoma 1Neoplasm Metastasis 1Melanoma 1Breast Neoplasms 1

Interventions

Specimen Handling 40Biopsy 39Magnetic Resonance Spectroscopy 31Cyclophosphamide 21aldesleukin 20fludarabine 16fludarabine phosphate 13Leucovorin 12Fluorouracil 12Interleukin-2 11Paclitaxel 9Melphalan 9Oxaliplatin 8trastuzumab deruxtecan 7Irinotecan 7X-Rays 6Taxes 6Nivolumab 6olaparib 5Ipilimumab 5CTLA-4 Antigen 5trametinib 4Neoadjuvant Therapy 4Floxuridine 4Doxorubicin 4Chemotherapy, Adjuvant 4Carboplatin 4veliparib 3talazoparib 3pembrolizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Neoplasm Metastasis × glembatumumab vedotin × Clear all
NCT03326258 2018-07-18

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
BreastDermatologic

Uveal Melanoma, Breast Neoplasms, Melanoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡